Ticking Off Investors, Akari CEO Exits Amid Coversin Trial Controversy
Akari, which is looking to ticks to provide a new PNH drug, has seen its CEO resign and investors launch class action suits amid controversy over a Phase II clinical trial for paroxysmal nocturnal hemoglobinuria.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.